Drug Trial Radar · NCT00124709
Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification
Last checked: Nov 19, 2026Latest source record: Mar 23, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,091
Actual
Start
Oct 2003
Primary completion
Jan 2008
Study completion Nov 2008
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 28, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 3 months, up to 18 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study consists of a 3-year double-blind phase during which patients will receive atopic dermatitis (AD) treatment either with pimecrolimus cream 1% long-term management (LTM) or with a conventional corticosteroid-based treatment (1:1 ratio), followed by a 2 to 3-year open-label (OL) phase (all patients receiving pimecrolimus cream 1% LTM). At the end of the double-blind phase, the two treatment groups will be compared with respect to their efficacy in controlling AD; at the end of the OL phase, the incidence of asthma at the age of 6 years will be compared.
Conditions
- Atopic Dermatitis
Interventions
PimecrolimusDrug
Pimecrolimus cream 1 %
CorticosteroidDrug
conventional corticosteroid-based treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Atopic Dermatitis (AD) Disease Control Over 36 MonthsTime frame: 36 months
- Effect of Early Use of Pimecrolimus Cream 1% in Reducing the Incidence of Asthma at 6 Years of AgeTime frame: 6 years
Locations
36 sites in 1 country. Site status is shown where the registry gives one.
Alabama Allergy and Asthma Center
Birmingham, Alabama
Northwest Arkansas Pediatric Clinic, P.A.
Fayetteville, Arkansas
The Children's Clinic of Jonesboro
Jonesboro, Arkansas
Southern California Research
Mission Viejo, California
Children's Hospital of Orange County
Orange, California
Stanford Dermatology Clinic and Clinical Trials Dept
Redwood City, California
Capital Allergy Respiratory Disease Center
Sacramento, California
Children's Hospital San Diego
San Diego, California
Allergy and Asthma Medical Group of Diablo Valley, Inc./ Clinical Research Division
Walnut Creek, California
National Jewish Medical and Research Center
Denver, Colorado
Dermatology Associates and Research
Coral Gables, Florida
Emerald Coast Clinical Research
Pensacola, Florida
Children's Memorial Hospital
Chicago, Illinois
Indiana University Outpatient Clinical Research
Indianapolis, Indiana
Central Kentucky Research Associates
Lexington, Kentucky
Dermatology Specialists
Louisville, Kentucky
Rx R & D
Metarie, Louisiana
Johns Hopkins Hospital
Baltimore, Maryland
Children's Hospital - Boston
Boston, Massachusetts
Dermatology, PLLC
Ann Arbor, Michigan
Mayo Clinic Rochester
Rochester, Minnesota
Central Dermatology
St Louis, Missouri
Skin Specialists, P.C.
Omaha, Nebraska
Dartmouth-Hitchcock Medical Center/Dermatology Section
Lebanon, New Hampshire
Children's Medical Group
Hopewell Junction, New York
Dermatology Associates of St. Luke's - Roosevelt
New York, New York
Calcagno Research and Development
Gresham, Oregon
Oregon Health Science University - Dermatology Dept.
Portland, Oregon
The Childrens' Hospital of Philadelphia
Philadelphia, Pennsylvania
Allegheny General Hospital
Pittsburgh, Pennsylvania
Tennessee Clinical Research Center
Nashville, Tennessee
Texas Children's Hospital, BCM
Houston, Texas
Alpine Medical Group, LLC
Salt Lake City, Utah
Granger Medical Clinic
West Valley City, Utah
Virginia Clinical Research
Norfolk, Virginia
Asthma Inc
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.